Shanghai Langsheng announces clinical trial approval of LX101 injection
Category: #health  By Pankaj Singh  Date: 2022-04-25
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Shanghai Langsheng announces clinical trial approval of LX101 injection

Shanghai Langsheng Biotechnology Co. Ltd has reportedly announced the clinical trial application of LX101 injection for treating patients with inherited retinal degenerations (IRD) associated with Rpe65 biallelic mutation.

This approval was given by the CDE (Center for Drug Evaluation) of the National Medical Products Administration (NMPA).

It should be noted that the Rpe65 gene mutation-induced Inherited retinal degeneration (IRD) is a rare disease that results in blindness. A breakthrough technology like gene therapy offers the possibility of fixing defective genes and reinstating normal gene functions.

Early comparative data suggested that the treatment aided IRD patients in improving vision and maintaining long-term therapeutic qualities.

Dr. Fenghua WANG, CEO of Shanghai Langsheng’s parent company Innostellar Biotherapeutics, expressed that this is a crucial achievement for the company.

LX101 has exhibited its therapeutic potential since the company collaborated with the National Clinical Research Center for Eye Diseases last year to perform the first IIT clinical research on IRD gene therapy.

Dr. WANG expects that more patients will benefit from LX101 with maximal treatment effects and therapeutic breakthroughs.

Being the earliest investor, the Innostellar team and Legend Capital collaborated on the pipeline planning, strategic decision, and design of the company structure organization. With constant backing to develop Innostellar, Legend Capital has supported the company in its two funding rounds.

In recent years, Legend Capital has been dedicated to systemic investment in the innovative medicine field. The company, sticking to the investment principle of Global Vision, Chinese Perspective, is seeking genuinely global competitive teams and technologies to solve unmet medical needs.

Simultaneously, Legend Capital has made investments in segment-leading firms like Glubio, Lynk Pharmaceuticals, Exegenesis Bio, Pegbio, and Suzhou Ribo Life Science.

For the record, Innostellar Biotherapeutics is a biopharma company focusing on gene therapy for discovering, manufacturing, and commercializing innovative drugs. The company closely works with China’s top clinical scientists and focuses on urgent patient needs.

Source credit:

https://www.benzinga.com/pressreleases/22/04/a26777521/legend-capitals-co-founded-company-innostellar-biotherapeutics-ird-gene-therapy-product-was-approv



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...